Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3
|
|
- Leona Wilson
- 6 years ago
- Views:
Transcription
1 Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study Arrigo F. G. Cicero, Sergio D Addato, Alessandra Reggi, Giulio Marchesini Reggiani & Claudio Borghi Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine ISSN Volume 8 Number 3 Intern Emerg Med (2013) 8: DOI /s
2 Your article is protected by copyright and all rights are held exclusively by SIMI. This e- offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com. 1 23
3 Intern Emerg Med (2013) 8: DOI /s CE - LETTER TO THE EDITOR Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study Arrigo F. G. Cicero Sergio D Addato Alessandra Reggi Giulio Marchesini Reggiani Claudio Borghi Received: 4 October 2012 / Accepted: 8 November 2012 / Published online: 25 November 2012 Ó SIMI 2012 Dear Editor, Non-alcoholic fatty liver disease (NAFLD) is a pathologic condition characterized by the deposition of triglycerides (TG) in the liver [5 % of the total liver weight, in the presence of alcohol consumption \10 g daily, involving % of the adult population in Western countries [1]. Progression of fatty liver to necroinflammation and fibrosis stages is not only a common cause of chronic liver disease but also a risk factor for increased all-cause mortality, type 2 diabetes and cardiovascular disease. The pathophysiological link among NAFLD, type 2 diabetes, and cardiovascular diseases seems to be insulin-resistance, which induces pathological ectopic fat accumulation combined with a low-grade chronic inflammatory state, in turn, resulting in abnormal glucose, altered fatty acid and lipoprotein metabolism, increased oxidative stress, deranged adipokine profile, hypercoagulability, endothelial dysfunction, and accelerated progression of atherosclerosis. This makes NAFLD the hepatic expression of the On behalf of the Brisighella Heart Study. A. F. G. Cicero Internal Medicine, Aging and Kidney diseases Department, Sant Orsola-Malpighi University Hospital, Poliambulatorio Pad. 2, Via Albertoni, 15, Bologna, Italy afgcicero@cardionet.it S. D Addato A. Reggi (&) G. M. Reggiani C. Borghi Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy alereggi@hotmail.it metabolic syndrome (MS). Epidemiological data support the hypothesis that MS is an independent risk factor for NAFLD, although it is difficult to distinguish which is the cause and which the effect. The main risk factors for NAFLD are also the components of MS, and a few observations suggest that NAFLD may develop independently of MS or also predict it [2]. The aim of our study is to evaluate if two inexpensive NAFLD indices are able to predict the 4-year MS incidence in a large population sample of pharmacologically untreated subjects. The Brisighella Heart Study (BHS) is a prospective, population-based longitudinal epidemiological investigation involving 2,939 randomly selected subjects (1,491 men and 1,448 women), aged years, free of cardiovascular disease at enrollment, who live in the northern Italian rural town of Brisighella. A detailed description of the BHS has been largely described elsewhere [3]. For the purpose of the present study, we considered a subsample of 824 pharmacologically untreated participants without MS, type 2 diabetes, cardiovascular disease, history of alcohol abuse, or known liver diseases (evaluated on the basis of patient reported history cross-matched with GPs databases, and on liver enzymes) in the 2004 population survey who were re-examined during the 2008 survey. We calculated, for all the subjects, the Hepatic Steatosis Index (HSI) [calculated as 8 9 (ALT/AST ratio)? body mass index (BMI) (?2 if woman;?2 if diabetes)] [4] and the Lipid Accumulation Product (LAP) {calculated as [waist circumference, WC (cm) - 65] 9 triglycerides, TG (mmol/l) for men and [WC (cm) - 58] 9 TG (mmol/l) for women} [5]. The main anthropometric, clinical and laboratory characteristics of the selected population during the 2004 and 2008 BHS surveys are summarized in Table 1: from 2004 to
4 266 Intern Emerg Med (2013) 8: Table 1 Descriptive analysis of available anthropometric, clinical, and laboratory data at 2004 and 2008 population surveys for the selected subjects (N = 824) Mean SD Mean SD Mean SD Mean SD Age (years) TC (mg/dl) Body mass index (kg/m 2 ) TG (mg/dl) Waist circumference (cm) HDL-C (mg/dl) Hip circumference (cm) LDL-C (mg/dl) Waist/hip ratio Non-HDL-C (mg/dl) Waist/height ratio ApoA1 (mg/dl) Pulse circumference (cm) ApoB (mg/dl) Arm circumference (cm) FPG (mg/dl) SBP (mmhg) SUA (mg/dl) DBP (mmhg) Creatinine (mg/dl) PP (mmhg) AST (U/L) MAP (mmhg) ALT (U/L) Heart rate (ppm) CPK (U/L) Breath rate (bpm) HSI LAP SBP systolic blood pressure, DBP diastolic blood pressure, PP pulse pressure, MAP mean arterial pressure, TC total cholesterol, LDL-C low density lipoprotein cholesterol, TG triglycerides, HDL-C high density lipoprotein cholesterol, Apo apolipoprotein, FPG fasting plasma glucose, SUA serum uric acid, AST aspartate aminotransferase, ALT alanine aminotransferase, CPK creatinine phospho-kinase, HSI Hepatic Steatosis Index, LAP Lipid Accumulation Product 2008, a non-significant trend to an increase in the levels of all the MS components, as defined by the third Adult Treatment Panel of the National Cholesterol Education Program, was observed. The predicting role of LSI and lnlap for MS was tested by a Cox-regression analysis adjusted for the components of the MS, also including age, BMI, alcohol intake, and physical activity (estimated by validated questionnaires [3]), ALT, AST, serum uric acid, HIS, and lnlap. The analysis was later repeated according to gender, because both indices are gender-related (Fig. 1). A level of p=0.05 was considered significant for all the tests. We observed 46 new cases of MS (M: 25, F: 21) with an incidence of 1.4 % per year. Considering the whole population, in a model adjusted for the baseline MS components, the predictors of MS (R 2 = 0.59) were age (OR 1.13, 95 % CI , p \ 0.001), HSI (OR 1.17, 95 % CI , p \ 0.001), and lnlap (OR 1.16, 95 % CI , p \ 0.001). When repeating the prediction analysis by gender, in men the MS predictors (R 2 = 0.55) were age (OR 1.13, 95 % CI ), and lnlap (OR 1.17, 95 % CI ). In women the MS predictors (R 2 = 0.680) were age (OR 1.13, 95 % CI ), LSI (OR 1.20, 95 % CI ), and lnlap (OR 1.16, 95 % CI ). A liver biopsy and histological diagnosis using Kleiner s histological NAFLD activity score is the gold standard to ascertain the stage of the disease. The invasive nature of Fig. 1 Hepatic Steatosis Index (HSI) and Lipid Accumulation Product (LAP) level by gender at the study baseline liver biopsy inevitably limits this diagnosis; thus, noninvasive methods have been developed to diagnose NA- FLD. Such methods include the combination of clinical data with ultrasound, CT-scan, and magnetic resonance imaging. However, the screening of asymptomatic individuals using imaging techniques does not appear to be cost-effective, due to the high cost for mass screening and the need of trained professionals. Therefore, simple, noninvasive tests would be welcome to identify patients at high risk of NAFLD and to establish an appropriate NAFLD screening program.
5 Intern Emerg Med (2013) 8: The LAP and the HSI are two of such tests. The HSI contains heterogeneous components linked to liver fat, able to rule out NAFLD with a sensitivity of 93.1 %, or detect NAFLD with a specificity of 92.4 %, respectively [4]. LAP includes a measure of intra-abdominal fat depot (WC) and a measure of long-chain fatty acids that circulate in blood inside lipoproteins, thus combining anatomic and physiologic changes associated with over-accumulation of lipids in adults [5]. We find that the scores of the two algorithms predicting the presence of fat in the liver (HSI) and fat accumulation (LAP) with time also predict the development of MS in subjects free of MS at baseline. Among the limitations of our study, we did not evaluate the prevalence of NAFLD by ultrasonography or by more sophisticated techniques. However, we have used validated NAFLD indices, useful for screening purposes in the general population. In our large population sample of healthy subjects more expensive or invasive diagnostic tests would be a priori neither ethical nor cost-effective. Finally, other confounding variables might have influenced our results, but the regression analyses were adjusted for a large number of parameters, so we trust our observation. In conclusion, both LAP and HSI, as correlates of NAFLD, are significant middle-term predictors of incident MS in a large sample of general population. Acknowledgments This study was supported by institutional funding of the University of Bologna, Italy. Conflict of interest References None. 1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the nutrition and liver study. Hepatology 42: Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G (2010) From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42: Cicero AFG, Dormi A, D Addato S, Borghi C, On behalf of the Brisighella Heart Study Staff (2011) From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the. Clin Lipidol 6: Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42: Bedogni G, Kahn HS, Bellentani S, Tiribelli C (2010) A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 10:98
American Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION
More informationAssociation between metabolic syndrome and the development of non-alcoholic fatty liver disease
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 77-84, 2013 Association between metabolic syndrome and the development of non-alcoholic fatty liver disease YI WANG 1, YU YUAN LI 2, YU QIANG NIE 2, YONG JIAN ZHOU
More informationThe classical metabolic work-up, approved by the Ethics Committee of the Antwerp
SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationHigher non-hdl-cholesterol to HDLcholesterol ratio linked with increased nonalcoholic steatohepatitis
Wang et al. Lipids in Health and Disease (2018) 17:67 https://doi.org/10.1186/s12944-018-0720-x RESEARCH Open Access Higher non-hdl-cholesterol to HDLcholesterol ratio linked with increased nonalcoholic
More informationBackground of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease
ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the
More informationBERBERINE INDUCED IMPROVEMENT IN HEPATIC STEATOSIS INDEX IN OVERWEIGHT DYSLIPIDAEMIC PATIENTS TREATED WITH LIPID-LOWERING NUTRACEUTICALS
CURRENT TOPICS IN NUTRACEUTICAL RESEARCH Vol. 11, No. 1/2, pp. 41-46, 2013 ISSN 1540-7535 print, Copyright 2013 by New Century Health Publishers, LLC www.newcenturyhealthpublishers.com All rights of reproduction
More informationThyroid Function and Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects
Thyroid function and NAFLD., 2018; 17 (5): 779-788 ORIGINAL ARTICLE September-October, Vol. 17 No. 5, 2018: 779-788 779 The Official Journal of the Mexican Association of Hepatology, the Latin-American
More informationAbdominal Obesity and Fatty Liver
Epidemiologic Reviews Copyright ª 2007 by the Johns Hopkins Bloomberg School of Public Health All rights reserved; printed in U.S.A. Vol. 29, 2007 DOI: 10.1093/epirev/mxm002 Advance Access publication
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationThe association between white blood cell subtypes and prevalence and incidence of nonalcoholic fatty liver disease
834477EJI0010.1177/2058739219834477European Journal of InflammationZhang et al. letter2019 Letter to the Editor The association between white blood cell subtypes and prevalence and incidence of nonalcoholic
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationEFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS
42 EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS Prasong Tienboon MD, PhD. 1, Taned Chitapanarux MD. 2, Suwalee Pojchamarnwiputh MD. 3, Donrawee Leelarungrayub
More informationThe effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.63 Insulinemic Status and Nonalcoholic
More informationDevelopment and validation of a simple index system to predict nonalcoholic fatty liver disease
The Korean Journal of Hepatology 2011;17:19-26 DOI: 10.3350/kjhep.2011.17.1.19 Original Article Development and validation of a simple index system to predict nonalcoholic fatty liver disease Young Jin
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationZhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: AMeta-analysis of Prospective Studies Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationEASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease.
Commentary. EASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease. Christopher D. Byrne 1,2, Giovanni Targher 3 1 Nutrition and Metabolism, Faculty of Medicine,
More informationNon-alcoholic fatty liver disease (NAFLD) is a
Original Article / Liver Hepatobiliary & Pancreatic Diseases International The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population Shou-Wu Lee, Teng-Yu Lee,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery
More informationScreening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
More informationScreening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016
Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationNIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.
NIH Public Access Author Manuscript Published in final edited form as: Am J Med Sci. 2014 January ; 347(1):. doi:10.1097/maj.0b013e31828b25a5. Association Between Metabolic Syndrome and Its Individual
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationPrediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects
Tokai J Exp Clin Med., Vol. 37, No. 4, pp. 12-16, 212 Prediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects Masako NEGAMI, Eiko TAKAHASHI, Hiroki OTSUKA and Kengo MORIYAMA
More informationReplacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins
Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins Muller H, Jordal O, et al. (998) Replacement of partially hydrogenated soybean
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More informationDownloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD
logistic regression Student s t-test P< BMI BMI P< ALT AST P< Email:mkhoshbaten@yahoo.com Kg/m2 NASH RUQ B C II Case-Control II Logistic Regression Chi-Square T-test P< Grade Model 1- A diffuse hyper echoic
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationNon-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital
WELCOME Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital Presented by DR. PRABIR MOHAN BASAK ASSISTANT PROFESSOR DEPARTMENT
More informationReproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)
Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD) Pr Sophie Christin-Maitre Reproductive Endocrine Unit, Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie INSERM U933 Paris, France
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationprogramme. The DE-PLAN follow up.
What are the long term results and determinants of outcomes in primary health care diabetes prevention programme. The DE-PLAN follow up. Aleksandra Gilis-Januszewska, Noël C Barengo, Jaana Lindström, Ewa
More informationPrevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study
Foschi et al. BMC Gastroenterology (2018) 18:177 https://doi.org/10.1186/s12876-018-0906-8 RESEARCH ARTICLE Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the
More informationShihui Fu 1,2, Ying Lin 2, Leiming Luo 1* and Ping Ye 1*
Fu et al. BMC Gastroenterology (2017) 17:49 DOI 10.1186/s12876-017-0607-8 RESEARCH ARTICLE Open Access The relationship of serum alanine aminotransferase normal-range levels to arterial stiffness and metabolic
More informationPREVALENCE OF NON-ALCOHOLIC FATTY LIVER IN A HYPERCHOLESTEROLEMIC POPULATION OF NORTHWESTERN PENINSULAR MALAYSIA
PREVALENCE OF NON-ALCOHOLIC FATTY LIVER IN A HYPERCHOLESTEROLEMIC POPULATION OF NORTHWESTERN PENINSULAR MALAYSIA Enrico Magosso 1, Mukhtar Alam Ansari 2, Yogheswaran Gopalan 1, Mohamed Rizal Abu Bakar
More informationAssociation between Abnormal Liver Function and Risk Factors for Metabolic Syndrome among Freshmen
Journal of Adolescent Health 41 (2007) 132 137 Original article Association between Abnormal Liver Function and Risk Factors for Metabolic Syndrome among Freshmen Ping-Yun Tsai, M.D. a, Chung-Jen Yen,
More informationChange in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study
Han et al. Clinical Hypertension (2015) 21:22 DOI 10.1186/s40885-015-0032-7 RESEARCH Open Access Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study
More informationThe Egyptian Journal of Hospital Medicine (Apr. 2017) Vol. 67(1), Page
The Egyptian Journal of Hospital Medicine (Apr. 2017) Vol. 67(1), Page 415-424 Assessment of Left Ventricular Diastolic Function in Nonalcoholic Fatty Liver Disease Mohamed Elhussein Mohamed Ali Elnahas
More informationDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam , Republic of Korea 2)
Endocrine Journal 2013, 60 (12), 1295-1301 Or i g i n a l The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase
More informationIS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE?
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 3 INTERNAL MEDICINE - PEDIATRICS UPDATES IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE? R. S. Gavril 1, Laura Mihalache
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationNon-alcoholic Fatty Liver Disease (NAFLD) and its association with metabolic syndrome and cardiovascular diseases
Non-alcoholic Fatty Liver Disease (NAFLD) and its association with metabolic syndrome and cardiovascular diseases Dr. Meenaxi Sharda 1, Dr. Deepti Yagnik 2, Dr. Anil Soni 3 and Dr. Harish Nigam 4 1 Professor,
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationZhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang, MF; Yu, Y; Lin, XP; Lam, CLK
Title Development and validation study of a non-alcoholic fatty liver disease risk scoring model among adults in China Author(s) Zhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang,
More informationNon-alcoholic fatty liver disease and associated risk factors among hemodialysis patients
Non-alcoholic fatty liver disease and associated risk factors among hemodialysis patients Sima Golmohamadi Hamid Reza Omrani Nadia Asadi Lotfollah Asgari Zahra Fathi Department of Internal Medicine, School
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationMetabolic defects underlying dyslipidemia in abdominal obesity
Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/
More informationAlarming high levels of transaminases in non insulin dependent diabetes mellitus
Original article: Alarming high levels of transaminases in non insulin dependent diabetes mellitus *Ekta Chitkara Department of Applied Medical Sciences, Lovely Professional University, Punjab, India *Corresponding
More informationThe Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community
International Journal of Scientific and Research Publications, Volume 4, Issue 4, April 214 1 The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community Mulugeta
More informationFast-food, Fatty liver, & Insulin Resistance. Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna
Fast-food, Fatty liver, & Insulin Resistance Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna Supersize Me Unhealthy Effects of Fast Food After consuming three meals a day
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS
FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS DR. ABDUL JABBAR, MBBS DR. ABDUL BASIT, MBBS DR. HAFIZ MUHAMMAD HANNAN AKBAR, MBBS ABSTRACT
More informationDisclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease
Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic
More informationIL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA
UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia
More informationNonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse
Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis
More informationEffect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease
Liver International ISSN 1478-3223 METABOLIC AND STEATOHEPATITIS Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease Hellan K. Kwon 1, Joel K. Greenson
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationUniversity of Padova, Padua, Italy, and HARVEST Study Group, Italy
University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini
More informationJournal of Adolescent Health 42 (2008) Original article. Manuscript received September 5, 2007; manuscript accepted November 27, 2007
Journal of Adolescent Health 42 (2008) 543 548 Original article Presence of the Metabolic Syndrome in Obese Adolescents Predicts Impaired Glucose Tolerance and Nonalcoholic Fatty Liver Disease Kathy A.
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationAssociations between Bright Pancreas and Features of Metabolic Syndrome
Japan Society of Nigen Dock ORIGINAL ARTICLE Ningen Dock 2012 ; 26 : 935-943 Associations between Bright Pancreas and Features of Metabolic Syndrome Akihiro Obora 1,2), Takao Kojima 1,2), Takahiro Kato
More informationNonalcoholic Fatty Liver Disease in a Sample of Iranian Women with Polycystic Ovary Syndrome
Original Article Nonalcoholic Fatty Liver Disease in a Sample of Iranian Women with Polycystic Ovary Syndrome Abstract Introduction: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More informationLiver Fat Quantification
Liver Fat Quantification Jie Deng, PhD, DABMP Department of Medical Imaging May 18 th, 2017 Disclosure Research agreement with Siemens Medical Solutions 2 Background Non-alcoholic fatty liver diseases
More informationOpen Access Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease
18 The Open Hypertension Journal, 2013, 5, 18-22 Send Orders for Reprints to reprints@benthamscience.net Open Access Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationSerum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease
Review Research Article Diabetes Management Serum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease Feng-Hwa Lu 1, Horng-Yih Ou 2, Hung-Tsung Wu 1,3, Hao-Chang
More informationNonalcoholic fatty liver disease (NAFLD) and nonalcoholic. Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1162 1168 Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients SVEN M. A. FRANCQUE,* AN VERRIJKEN, ILSE MERTENS, GUY
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationCosmas Rinaldi A. Lesmana 1,2*, Levina S. Pakasi 1, Sri Inggriani 3, Maria L. Aidawati 3 and Laurentius A. Lesmana 1
Lesmana et al. BMC Gastroenterology (2015) 15:174 DOI 10.1186/s12876-015-0404-1 RESEARCH ARTICLE Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up
More informationSupplementary Table 1. Patient demographics and baseline characteristics (treated patients).
Supplementary Table 1. Patient demographics and baseline characteristics (treated patients). Placebo (n=188) 10 mg (n=186) 25 mg (n=189) Total (n=563) Gender, n (%) Male 75 (40) 97 (52) 84 (44) 256 (45)
More informationAtherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study
WANG et al. Lipids in Health and Disease (2018) 17:284 https://doi.org/10.1186/s12944-018-0932-0 RESEARCH Open Access Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease
More informationLearning Objectives. Disclosures. Self Assessment Questions. Background
Association of Hyperuricemia with Liver Dysfunction amongst Adults with Metabolic Disorders in the United States: A Cross Sectional Study Disclosures Dr. Prashant Sakharkar and Dr. Subrata Deb declare(s)
More informationRisk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study
Liu et al. Lipids in Health and Disease (2018) 17:221 https://doi.org/10.1186/s12944-018-0865-7 RESEARCH Open Access Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD):
More informationLiver Enzymes Concentrations Are Closely Related to Pre diabetes: Findings of the Shanghai Diabetes Study II (SHDS II) *
30 Biomed Environ Sci, 2012; 25(1): 30 37 Original Article Liver Enzymes Concentrations Are Closely Related to Pre diabetes: Findings of the Shanghai Diabetes Study II (SHDS II) * GAO Fei 1, PAN Jie Min
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro
More informationUnraveling the concealed and calculated cardiovascular risks in diabetes
15 P B Fernando Memorial Oration 2015 Unraveling the concealed and calculated cardiovascular risks in diabetes Weerarathna T P 1 Journal of the Ceylon College of Physicians, 2016, 47, 15-19 Abstract Cardiovascular
More information